Renovacor

Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy - Acquisition further strengthens Rocket’s leadership in AAV-based cardiac gene therapy and expands Company’s near-term clinical assets for the treatment of heart conditions  - Significant unmet medical need in BAG3-associated dilated cardiomyopathy, with meaningful commercial opportunity, comparable to Danon…

Renovacor Reports Second Quarter 2022 Financial Results and Provides Corporate Update REN-001 IND submission planned for the second half of 2022 Data from pilot pig study showing successful cardiac transduction with REN-001 delivered via low-dose retrograde coronary sinus infusion published in Journal of the American College of Cardiology: Basic to…

Renovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of Arrhythmogenic Cardiomyopathy Research collaboration with the University of Utah's Nora Eccles Harrison Cardiovascular Research and Training Institute expands pipeline with the addition of an AAV gene therapy program for multiple genetic segments of arrhythmogenic cardiomyopathy See more…

Renovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered Via Low-Dose Retrograde Coronary Sinus Infusion Published in Journal of the American College of Cardiology: Basic to Translational Research REN-001 delivered locally via low-dose retrograde coronary sinus infusion demonstrated robust, diffuse cardiomyocyte transduction in a large…

Renovacor Reports First Quarter 2022 Financial Results and Provides Corporate Update REN-001 advancing toward IND submission in the second half of 2022 with the initiation of a Phase I/II clinical trial in BAG3-DCM expected thereafter Strengthened executive team with appointment of Fred Driscoll as CFO See more here

Renovacor Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Debuted as a public company and raised gross proceeds of $95.1 million from the business combination with Chardan Healthcare Acquisition 2 Corp and a concurrent PIPE financing Strengthened company leadership with key appointments including Marc Semigran,…

Renovacor Announces Partnerships with the Dilated Cardiomyopathy Foundation, the Heart Failure Society of America and the American Association of Heart Failure Nurses to Help Increase Awareness of Genetic Heart Disorders See more here

Renovacor Announces Third Quarter 2021 Financial Results and Provides Corporate Update Debuted as a public company and strengthened liquidity position with $95.1 million in gross proceeds from the business combination with Chardan Healthcare Acquisition 2 Corp and concurrent PIPE financing Released topline preclinical data demonstrating feasibility of REN-001 to transduce…

Renovacor Announces the Appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations Dr. Dhanasekharan joins Renovacor with extensive experience overseeing development, manufacturing and supply operations for biologics including AAV gene therapies See more here

Renovacor Announces the Appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science Dr. Shin to help advance REN-001 into the clinic by leveraging nearly two decades of expertise in clinical development, academic research and medical practice See more here